Axalta Q2 Earnings: Merger Costs Weigh on Profit Ahead of Aug. 5 Vote
AXTA sits 42% above its 52-week low of $24.937 on light trading volume (0.2× avg).
Summary
Axalta reported Q2 2026 net income of $89 million ($0.41 diluted EPS) on sales of $1.35 billion, with $35 million in merger costs weighing on profits. The shareholder vote on the AkzoNobel merger is set for August 5, 2026.
Key Events · Earnings and Guidance · AXTA
-
Q2 Earnings Hit by Merger Costs
Net income fell to $89M ($0.41 diluted EPS) from $109M a year ago, as $35M in merger-related costs and a higher tax rate (24.7% vs. 23.2%) offset a 3.1% sales increase to $1.35B.
-
Merger Vote Set for August 5
Shareholders will vote on the all-stock AkzoNobel merger next week. The deal, amended twice most recently on July 23, would create a dual-headquartered coatings giant.
-
Debt Prepayment Strengthens Balance Sheet
Axalta prepaid $125M of its 2029 Dollar Term Loans, reducing total borrowings to $3.07B. The $500M 2027 Senior Notes remain classified as current, with repayment or refinancing expected before maturity.
-
Merger-Related Costs Surge
Merger and acquisition-related costs reached $57M year-to-date, up from $6M in the prior year, primarily driven by the proposed AkzoNobel combination. These costs are non-deductible, pushing the effective tax rate higher.
Analysis · AXTA · Industrial Applications And Services
Axalta's Q2 results show modest sales growth but a sharp drop in operating income, driven by $35 million in merger-related costs tied to the pending AkzoNobel combination. The effective tax rate jumped to 24.7% as those costs are non-deductible. The company also prepaid $125 million of term loans, strengthening the balance sheet ahead of the merger. With the shareholder vote just a week away, these results highlight the near-term earnings drag from the deal, even as the underlying business holds steady.
At the time of this filing, AXTA was trading at $35.32 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $24.94 to $35.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.